
Article

Fusaricidins, polymyxins and volatiles produced by *Paenibacillus polymyxa* strains DSM 32871 and M1

Pascal Mülner^{1,3}, Elisa Schwarz¹, Kristin Dietel¹, Stefanie Herfort², Jennifer Jähne², Peter Lasch², Tomislav Cernava³, Gabriele Berg³, Joachim Vater²

¹ ABITEP GmbH, Glienicker Weg 185, 12489 Berlin, Germany;

Schwarz@abitep.de; Dietel@abitep.de

² Robert Koch-Institut, ZBS6, Proteomics and Spectroscopy, Seestr 10, 13353 Berlin, Germany;

HerfortS@rki.de; JaehneJ@rki.de; LaschP@rki.de

³ Institute of Environmental Biotechnology, Graz University of Technology, Petergasse 12, 8010 Graz, Austria

pascal.muelner@tugraz.at; tomislav.cernava@tugraz.at; gabriele.berg@tugraz.at

Correspondence: Dr. Joachim Vater, Robert Koch-Institut, ZBS6, Seestr. 10, 13353 Berlin, Germany;

vatermj@web.de

Abstract: *Paenibacilli* are efficient producers of potent agents against bacterial and fungal pathogens, which are of great interest both for therapeutic applications in medicine as well as in agrobiotechnology. Lipopeptides produced by such organisms play a major role in their inactivation potential. In this work we investigated two lipopeptide complexes, the fusaricidins and the polymyxins, produced by *Paenibacillus polymyxa* strains DSM 32871 and M1 by MALDI-TOF mass spectrometry. The fusaricidins show potent antifungal activities and are distinguished by an unusual variability. For strain DSM 32871 we identified numerous yet unknown variants mass spectrometrically. DSM 32871 produces polymyxins of type E (colistins), while M1 forms polymyxins P. For both strains novel, but not yet completely characterized polymyxin species were detected, which possibly are glycosylated. These compounds may be of interest therapeutically, because polymyxins attain increasing attention as last-resort antibiotics against multiresistant pathogenic Gram-negative bacteria. In addition, the volatiles of DSM 32781 and M1 were investigated with a GC-MS approach using different cultivation media. Production of volatile organic compounds (VOCs) was strain and medium dependent. In particular, strain M1 manifested as an efficient VOC-producer that exhibited formation of 25 volatiles in total. A characteristic feature of *Paenibacilli* is the formation of volatile pyrazine derivatives.

Keywords: *P. polymyxa*; bioactive peptides; volatiles; MALDI-TOF mass spectrometry; GC-MS

1. Introduction

Paenibacillus spp. are distinguished by a large arsenal of bioactive secondary metabolites, such as nonribosomally formed lipopeptides, lassopeptides, polyketides, lantibiotics and bacteriocines, which are of high importance both in agrobiotechnology and medicine [1-4]. They are efficient producers of potent agents against both bacterial and fungal pathogens. The most abundant bioactive compounds of these organisms are lipopeptides, which cover a broad range of structurally diverse linear and cyclic species with peptide chain lengths between 6 and 13 amino acids and manifold variations in their fatty acid chains. They comprise fusaricidins and the related LiF-antibiotics (cyclic

lipohexapeptides connected with a guanidinilated β -hydroxy fatty acid with chain lengths between 13-19 carbon atoms) [5-12]; paenilipoheptins (cyclic lipopeptides; β -amino fatty acid) [13]; octapeptins (cyclic lipooctapeptides; β -hydroxy fatty acid) [1, 14]; polypeptins (cyclic lipononapeptides; β -hydroxy fatty acid) [1,15]; pelgipeptins (cyclic lipononapeptides; β -hydroxy fatty acid) [1,16]; polymyxins (cyclic lipodecapeptides; C8,9-unsubstituted fatty acids) [1, 17]; tridecapeptins (linear lipotridecapeptides; β -hydroxy fatty acids) [1, 18-20] and paenibacterins (cyclic lipotridecapeptides; pentadecanoic acid) [21,22]. A promising prospect for medical application of these agents is that some of them display strong activities against multidrug-resistant pathogens covering both Gram-negative as well as Gram-positive bacteria. Therefore, they may be a valuable resource for the development of novel antibiotics to overcome the increasing problem of antibiotic resistance. In particular, the exploitation of the bioactive agents produced by *P. polymyxa* may contribute to solve this insistent public health issue.

The present study is focused on *Paenibacillus polymyxa* strains, which are efficient plant growth-promoting rhizobacteria (PGPR) colonizing surfaces of plant roots in the rhizosphere [23-25]. They also appear as endophytes within the plant [26,27]. Such strains produce four classes of lipopeptides, the fusaricidins, paenilipoheptins, polymyxins and tridecaptins. All of them comprise numerous structural homologs. In particular, fusaricidins [10-12] show an unusual complexity of isoforms providing a large spectrum of closely related agents with graduated activities against fungal pathogens. In this work we investigated the fusaricidin and polymyxin complexes produced by *P. polymyxa* DSM 32871 in comparison to those formed by the well-characterized strain M1 as model organism.

Fusaricidins were discovered by Kakinuma et al. [5,6] and thereafter investigated by other authors in detail [7-9]. They provide a large reservoir of potent antifungal biocontrol agents against a broad array of phytopathogenic fungi, such as *Fusarium* strains [26,28], *Rhizoctonia solani* [25], *Leptosphaeria maculans* [29], *Sclerotinia sclerotiorum* [25] and *Botrytis cinerea* [25], for examples. They are commonly used to cure plant diseases, such as fusarium wilt of cucumber [28]; gibberella ear rot of maize [26]; blacklag disease of canola [29] or bacterial leaf blight in rice [30].

Polymyxins are cationic cyclic lipodecapeptides, which also appear as a family of closely related variants [17, 31]. They are positively charged because of the free amino groups of five of their six 2,4-diaminobutyric acid (Dab) components. They are dissected into three characteristic structural elements. They are acylated at their N-terminal Dab-residue either by S-6-methyl octameric acid or (S)-6-methyl heptanoic acid. Dab (1) is part of a linear tripeptide segment Dab(1)-Thr(2)- Dab(3)-. Dab (4) is involved in formation of a heptapeptide ring by condensation of its free amino group with the carboxyl group of the C-terminal Thr (10). The heptapeptide ring harbors a variable hydrophobic motif at positions R(6) and R(7). These residues appearing in D-configuration are specific for the polymyxin type and can therefore be used for the classification of these antibiotics. The therapeutically most important species are polymyxin B [17] and polymyxin E (colistin) [32-34]. Polymyxins E are produced by *P. polymyxa* DSM 32871. Here positions 6 and 7

are occupied by two leucine residues, while for polymyxin B Leu (6) is replaced by Phe. The hydrophobic motif of polymyxin P produced by strain M1 is D-Phe-D-Thr [35,36]. Polymyxins are in focus as last resort antibiotics against multiresistant Gram-negative pathogens, such as the majority of *Enterobacteriaceae*, *K. pneumoniae*, *A. baumannii* or *P. aeruginosa* [37,38]. The therapeutic application of polymyxins certainly is the most important public interest, but beyond this there are also promising aspects for their usage as biocontrol agents in plant biotechnology. Recently, polymyxin P was demonstrated to suppress phytopathogenic *Erwinia* spp., the causative pathogen of fire blight and soft rot diseases [39].

Another class of attractive microbial secondary metabolites exhibiting manifold important activities are volatile organic compounds (VOCs), which display high chemical diversity [40-42]. They gain increasing attention particularly concerning plant growth promotion [43-45], biocontrol against bacterial and fungal pathogens [44,45] and induction of systemic resistance against phytopathogens [46-48].

In our work we performed comprehensive studies on the variety of the fusaricidin and polymyxin lipopeptide complexes produced by *P. polymyxa* DSM 32871 and M1 by MALDI-TOF mass spectrometry. These antifungal and antibacterial agents are of high relevance for inactivation of both human and plant pathogens. In addition, the diversity of volatile organic compounds (VOCs) released by these strains was studied with a specific headspace GC-MS analysis method under different growth conditions.

2. Results

In this work we investigated the biosynthetic potential of the *Paenibacillus polymyxa* strain DSM 32871. Its product pattern was compared with that of the well characterized M1 strain [10,11], which was implemented as a model strain. To explore the antimicrobial capacity of these strains we investigated their biosynthetic products by MALDI-TOF mass spectrometry in a time and space dependent fashion. We focused on two lipopeptide complexes, the fusaricidins and the polymyxins, as well as their volatiles which facilitate long-range interactions with plants and their native microbiota in the rhizosphere.

For this purpose, DSM 32871 and M1 were grown in various cultivation media (Landy, LOP, LB, TSA and GSC). Samples were taken at growth times of 12; 24; 48; 72 and 96 h to investigate the time profile of the production of the tested bioactive compounds and to determine their specific location. It was assessed, whether they were residing in the cell or at the outer cell wall, or if they were released into the cultivation media. Fig. 1 shows MALDI-TOF mass spectra of surface extracts (Figs. 1A and C) and culture filtrates (Figs. 1B and D) of DSM 32871 and M1 in the mass range of 800 – 2000 Da indicating three lipopeptide complexes, the fusaricidins, polymyxins and tridecaptins. The strains were cultivated in the LOP medium. Surface extracts were prepared by extraction of cell material obtained from agar plates with 50% ACN/ 0.1% TFA. Fusaricidins and tridecaptins preferentially were found attached to the outer surface of the *Paenibacillus* strains, while the polymyxins were mainly released into the cultivation media. At growth times higher than 48 h fusaricidins were also enriched in the culture filtrates.




Figure 1. MALDI-TOF mass spectra of surface extracts of *P. polymyxa* DSM 32871 (A) and M1 (B) after growth for 72h on Landy agar plates and in the culture filtrates after growing these strains in the LOP medium (C and D) in the mass range of $m/z = 800 - 2000$ Da. Surface extracts were obtained by extraction of cell material with 50% acetonitrile/0.1% trifluoroacetic acid.

In particular, the fusaricidin complex is distinguished by an unusually high variability [11]. Its composition depends on the growth medium as is apparent from Fig. S1 for cultivation of DSM 32871 and M1 in the Landy/LOP and LB medium. Interestingly, for DSM 32871 grown in the Landy or LOP medium in the MALDI-TOF mass spectra (Fig. S1A and Fig. 2A) fusaricidins A and B with molecular masses of $m/z = 883.9$ and 897.9 and their derivatives at $m/z = 954.9$ and 968.9 differing from the parent ions by a mass difference of 71 Da were prevalent, while for DSM 32871 grown in the LB medium and for M1 cultivated in both the Landy/LOP and the LB media fusaricidins A, B, C ($m/z = 947.9$) and D ($m/z = 961.9$) were the prominent species.

The culture filtrate of DSM 32871 grown for 48 h in the LOP medium (Fig. 2A) was fractionated by reversed phase HPLC on a 300 SB-C8 Zorbax column. The chromatogram in Fig. 2B shows product fractionation in fractions 20 to 30. MALDI-TOF mass spectra of aliquots of fractions 22-30 are shown in Figs. 2S A-K demonstrating the separation of the produced compounds. Fusaricidins are the main products of DSM 32871. They were distributed among a broad range in fractions 22-30. Polymyxins appeared in fractions 22 and 23. Tridecaptins were found in fractions 28-30.




Figure 2. A. MALDI-TOF mass spectrum of the culture filtrate of *P. polymyxa* DSM 32871 cultivated in the LOP medium for 48 h in the mass range of $m/z = 800 - 1040$ covering the fusaricidin complex. B. HPLC-chromatogram demonstrating fractionation of the culture filtrate of DSM 32871. The ordinate shows scales for the absorption at 210 nm in mAu and for the percentage of the eluent acetonitrile. The abscissa indicates the fraction number and the elution time.


Table 1. Fusaricidins produced by *P. polymyxa* DSM 32871.

	fusaricidins		fragment a	fragment b	HPLC-fraction
	m/z	m/z+71	m/z	m/z	
	855.51		256.10 (C15)	600.16	24
			228.09 (C13)	628.18	
		926.55	256.0	671.42	24
	869.53		256.15 (C15)	614.12	25
			228.18 (C13)	642.21	
		940.57	256.09	685.15	24
A	883.53		256.25	628.32	26
A		954.57	256.21	699.21	25
B	897.58		256.29	642.38	27
B		968.62	256.19	713.22	25
E	911.55		256.26	656.16	27/28
E		982.62	256.26	727.32	26
F	925.58		256.22	670.22	28/29
F		996.65	256.20	741.34	27/28
C	947.51		256.28	692.28	25
C		1018.58	256.21	763.19	25
D	961.55		256.20	706.23	25
D		1032.61	256.17	777.10	25
	m/z+16	m/z+71			
A	899.55		272.18	628.27	22
A		970.51	272.13	699.22	22/23
B	913.57		272.12	642.16	22/23
B		984.52	272.15	713.25	22/23
	m/z+14				
	897.25		270.15	628.25	23
	911.24		270.10	642.16	23

The fusaricidins produced by *P. polymyxa* DSM 32871 are summarized in Table 1. They comprise the well-known fusaricidins A-F [5,6,10,11]. In addition, fusaricidins were found at $m/z = 869.53$ and 855.51 which could be derived from fusaricidin A either by substitution of Thr (1) or both threonines in positions 1 and 4 by serines, respectively. Apparently, three series of new fusaricidin species were detected. For DSM 32871 the occurrence of derivatives of all these fusaricidins was characteristic, which differ from their parent ions by a mass difference of 71 Da indicating modification by attachment of an alanine residue. These variants were among the dominating species in the mass spectra of DSM 32871. In addition, for this strain two other yet unknown fusaricidins with molecular masses of $m/z = 899.6$ and 913.6 were found. They are related to fusaricidins A and B with a mass difference of 16 Da, indicating a hydroxylation of these species. Also, for these new fusaricidins +71-derivatives ($m/z = 970.5$ and 984.5) appeared. All these variants were either not found or are present in only low amount in samples

of the reference strain M1. The structure of all these new fusaricidins were investigated by fragment analysis using LIFT-MALDI-TOF/TOF mass spectrometry [49]. Fragment spectra for fusaricidin A ($m/z = 883.5$) (A) and related compounds ($m/z = 954.6$ (B) and 899.6 (C)) are shown in Fig. 3 A-C.

In previous studies [10,11] we demonstrated that by laser excitation fusaricidins preferentially are decomposed in β -position to the carboxyl group of their fatty acid residue forming two characteristic *fragments a and b* according to the fragment pattern displayed in scheme 1 for ring-opened fusaricidin A:



Scheme 1. Decomposition of fusaricidin A on laser excitation.

Fragment a functions as an indicator for the fatty acid constituent of fusaricidins which is shortened by the two carbon atoms at its C-terminal end, which are connected via the carboxyl group of the fatty acid component with the amino group of the starter amino acid being part of *fragment b* containing the complete peptide chain. In Fig.3 the mass peak of *fragment a* was strongly dominating in the product ion spectra of fusaricidins, while *fragment b* appeared with substantially lower intensity. *Fragment b* was visualized in the expanded mass region from $m/z = 600$ -720. The molecular masses for the fusaricidins produced by *P. polymyxa* DSM 32871 together with the mass data for the corresponding *fragment ions a and b* derived from the product ion spectra are summarized in Table 1.

In Fig. 3A and B the fragment spectrum of fusaricidin A with a C15-guanidino-pentadeca-3-hydroxy fatty acid chain is shown. As can be seen from scheme 1 [11] here the mass numbers of *fragments a and b* amount to $m/z = 256.3$ and 628.3, resp. For the +71-derivative the same value for *fragment a* was found as for the unsubstituted fusaricidin A (Fig. 3C), but *fragment b* as apparent in Fig. 3D was 71 mass units higher ($m/z = 699.2$) indicating that the modification is located in the peptide portion. In contrast, for the +16 variant of fusaricidin A ($m/z = 899.6$) *fragment a* $m/z = 272.2$ (Fig. 3 E) was 16 mass units higher than for the unsubstituted fusaricidin A, while

the peptide part ($m/z = 628.3$ for *fragment b*) remained unchanged (Fig. 3 F). Apparently, here the fatty acid part of the derivative is hydroxylated.




Figure 3. LIFT-MALDI-TOF/TOF product ion spectra of fusaricidin A ($[M + H]^+ = 883.74$) (A and B) and the novel derivatives of this compound with molecular masses $[M + H + 71]^+ = 954.63$ (C and D) and $[M + H + 16]^+ = 899.43$ (E and F), resp. A, C and E cover the complete product ion spectra exhibiting fragments a and the parent ions. B, D and F present the expanded mass range from $m/z = 600 - 720$ visualizing fragments b.

By evaluation of the LIFT-TOF/TOF product ion spectra of the fusaricidins produced by DSM 32871 listed in Table 1 a third group of yet unknown variants was found with molecular masses $m/z = 897.3$ and 911.2 , which revealed as derivatives of fusaricidins A and B, exhibiting a value of $m/z = 270.3$ for *fragment a*. According to the data for *fragment*

b of $m/z = 628.3$ and 642.2 they can be attributed to fusaricidins A and B bearing a C16-guanidino-3-hydroxy-hexadecameric acid as fatty acid constituent.

A	b_n found	$[M+H-H_2O-NH_3]^+$	263.22	364.27	463.32	562.36	663.46	777.58	848.82
	b_n found	$[M+H-H_2O]^+$	280.24	381.28	-	579.18	680.49	794.60	865.66
	b_n found	$[M+H]^+$	298.23	-	-	-	698.51	812.63	883.74
	b_n calc.	$[M+H]^+$	298.26	399.31	498.37	597.44	698.49	812.53	883.57
			GHPD	Thr (1)	Val (2)	Val (3)	a-Thr (4)	Asn (5)	Ala (6)
	y_n calc.	$[M+H]^+$	883.57	586.32	485.27	386.20	287.13	186.08	72.04
	y_n found	$[M+H]^+$	883.74	-	485.24	386.20	287.14	186.11	72.10
B	b_n found	$[M+H-H_2O-NH_3]^+$	263.22	364.27	463.30	-	-	848.74	-
	b_n found	$[M+H-H_2O]^+$	280.24	381.28	-	579.18	-	865.64	936.74
	b_n found	$[M+H]^+$	298.23	-	-	597.23	769.14	883.66	954.78
	b_n calc.	$[M+H]^+$	298.26	399.31	498.37	597.44	769.53	883.57	954.61
			GHPD	Thr	Val	Val	Ala ↓ a-Thr	Asn	Ala
	y_n calc.	$[M+H]^+$	954.61	657.36	556.31	457.24	358.17	186.08	72.04
	y_n found	$[M+H]^+$	954.78	-	-	-	358.18	186.11	72.10
C	b_n found	$[M+H-H_2O-NH_3]^+$	-	380.23	479.30	578.35	-	793.45	864.52
	b_n found	$[M+H-H_2O]^+$	296.19	397.25	-	-	-	810.48	881.43
	b_n found	$[M+H]^+$	-	415.29	514.30	-	-	828.50	899.43
	b_n calc.	$[M+H]^+$	314.24	415.29	514.36	613.43	714.48	828.52	899.56
			OH-GHPD	Thr	Val	Val	a-Thr	Asn	Ala
	y_n calc.	$[M+H]^+$	899.56	586.32	485.27	386.20	287.13	186.08	72.04
	y_n found	$[M+H]^+$	899.43	586.25	-	386.19	287.10	186.03	72.03

Figure 4. Sequence of fusaricidin A (precursor ion $[M + H]^+ = 883.74$) (A) and its derivatives modified at the hydroxyl group of D-allo-Thr in position 4 by alanine (precursor ion $[M + H + 71]^+ = 954.78$) (B) and by an additional hydroxyl group in its GDPH fatty acid side chain (precursor ion $[M + H + 16]^+ = 899.43$) (C) derived from their LIFT-TOF/TOF product ion spectra. Structural analysis was based on three sets of b_n -fragment ions, obtained either in their intact form or after elimination of H_2O ($b_n (-H_2O)$) as well as of both H_2O and NH_3 ($b_n (-H_2O; -NH_3)$), resp. They were corroborated by the corresponding series of y_n -ions.

In Figs. 4 A-C the complete sequence of fusaricidin A and its +71- and +16-variants obtained from series of b_n - and y_n -fragment ions are demonstrated. Indeed, unsubstituted fusaricidin A (Fig. 3A) and its +16-derivative (Fig. 3C) show the same peptide sequence, while the +71-variant (Fig. 3B) is substituted at its allo-threonine residue in position 4 by an alanine forming an ester bond with its free hydroxyl-group. This feature is corroborated by the sequence of the corresponding *fragments b* of fusaricidin A (Fig. 5A) and its +71-derivative (Fig. 5B). These results were substantiated by the product ion spectra in Fig. 3S A and B showing their upper part in expanded

version. Here the value of fragment b_4 ($m/z = 769.14$) is 71 mass units higher than b_4 of the unmodified fusaricidin A indicating substitution of allo-Thr in position 4 by an alanine. Correspondingly, b_5 ($m/z = 812.63$) is shifted to $m/z 883.66$ in the case of the +71-variant with a molecular mass of $m/z = 954.6$. This result is compatible with previous data obtained for fusaricidins C and D [10].

A

b_n found	[M+H-H ₂ O] ⁺	-	126.07	225.13	324.18	425.21	539.27	610.32
b_n found	[M+H] ⁺	42.92	144.07	-	-	-	-	628.32
b_n calc.	[M+H] ⁺	43.02	144.07	243.14	342.21	443.26	557.30	628.34
		CH ₃ -CO	Thr (1)	Val (2)	Val (3)	a-Thr (4)	Asn (5)	Ala (6)
y_n calc.	[M+H] ⁺	628.34	586.32	485.27	386.20	287.13	186.08	72.04
y_n found	[M+H] ⁺	628.32	-	485.24	386.20	287.14	186.11	72.10

B

b_n found	[M+H-H ₂ O] ⁺	-	126.07	225.13	324.18	-	610.18	-
b_n found	[M+H] ⁺	42.98	144.08	-	-	-	628.31	699.26
b_n calc.	[M+H] ⁺	43.02	144.07	243.14	342.21	514.30	628.34	699.38
		CH ₃ -CO	Thr	Val	Val	Ala ↓ a-Thr	Asn	Ala
y_n calc.	[M+H] ⁺	699.38	657.35	556.30	457.24	358.17	186.08	72.04
y_n found	[M+H] ⁺	699.26	-	-	-	358.13	186.08	72.07

Figure 5. Sequence of fragments b of fusaricidin A (A) and its derivative modified at the hydroxyl group of D-allo-Thr in position 4 by alanine determined by LIFT-TOF/TOF mass spectrometry.

In Fig. 6 and Table 2 the polymyxin products of the two investigated *P. polymyxa* strains are shown. DSM 32871 produces two isomers of polymyxin E (E1 and E2) with molecular masses $[M + H]^+ = 1155.7$ and 1169.8 (see Table 2), while M1 forms two variants of polymyxin P (P1 and P2) with masses of $[M + H]^+ = 1177.4$ and 1191.4 (Fig. 6C and Table 2) [38,39]. For both strains the isomers differ by a C8 or a C9 fatty acid. The protonated forms of these polymyxin families together with their alkali adducts are summarized in Fig. 6 and Table 2. Both polymyxins have a high affinity for potassium, as shown by the $[M - H + 2K]^+$ - ions indicating binding of two potassium atoms.

The structure of polymyxins E studied by LIFT-MALDI-TOF/TOF MS is presented in Fig. 7. Product ion spectra were taken either starting from the fatty acid constituent or the first amino acid Dab (1) (Fig. 7A) as well as from Dab (5) and Leu (6) (Fig. 7B) modelling the polymyxin structure from series of b_n and y_n - ions. The fatty acid residues show masses of $m/z = 126.1$ and 140.1 , resp. The obtained sequence of polymyxin E is in accordance with the data reported in the literature [37]. The structure of polymyxin P was presented in a previous paper [38,39].




Figure 6. MALDI-TOF mass spectra of the polymyxin families produced by *P. polymyxa* DSM 32871 (A and B) and M1 (C) detected in the culture filtrates of these strains which were grown in the LOP medium for 48 h. Spectrum A was recorded in the mass range $m/z = 1180$ - 1380 and shown in expanded form from $m/z = 1210$ - 1380 in B.

Interestingly, both for polymyxin E and P we observed a family of minor species apparent from Fig. 6 at the higher mass range. For example, mass peaks were found at $m/z = 1302.0$ and 1316.0 for polymyxin E as well as at $m/z = 1323.9$ and 1337.9 for polymyxin P each showing a mass difference of approximately 146 Da relating to the protonated unsubstituted forms of E1/E2 and P1/P2, respectively (see Table 2). These

species were sequenced by LIFT-MALDI-TOF/TOF MS. All of them showed the polymyxin sequence with a substitution of the Dab residue in position 4 by a threonine in combination with yet unknown structural elements at the C-terminal end of approx. 146 or 197 Da. This replacement was corroborated by nearest neighbor studies in Table 3 modeling the polymyxin structure by di-, tri-, tetra- and pentapeptide analysis. For example, in Fig. 8 sequencing of the species with a molecular mass of $m/z = 1316.0$ is demonstrated which is a derivative of polymyxin E2 modified at its C-terminal end with a residue of approximately 146 Da. Similar results were achieved for the corresponding E1 derivative with a molecular mass of $m/z = 1302.0$. These compounds show a higher hydrophobicity than the original polymyxins demonstrated in Figs. 6 and 7. In the HPLC-profile (Fig. 2B) they were found in fractions 28 and 29 together with the tridecaptins, while the unsubstituted polymyxins E appeared in fraction 23. The nature of the additional elements in the sequence of the minor species have still to be elucidated.

Table 2. Polymyxins produced by *P. polymyxa* strains DSM 32871 and M1.

	strain DSM 32871: polymyxin E	strain M1: polymyxin P
[M + H, Na, K] ⁺	E1: 1155.7/1177.8/1193.8 E2: 1169.8/1191.8/1207.8	P1: 1177.4/1199.3/1215.4 P2: 1191.4/1213.4/1229.3
[M – H + 2K] ⁺	E1: 1231.9 E2: 1245.9	P1: 1253.9 P2: 1267.9
[M + H + 146] ⁺	E1: 1302.0 E2: 1316.0	P1: 1323.9 P2: 1337.9
[M + H + 197] ⁺	E1: 1352.9 E2: 1366.9	

A

b_n found	[M+H-H ₂ O] ⁺	-	184.04	284.15	-	-	-	710.21	810.10	-	-	
b_n found	[M+H] ⁺	101.01	202.04	302.15	402.14	-	-	728.24	828.23	928.75	1029.20	
b_n calc.	[M+H] ⁺	101.07	202.12	302.18	402.25	502.31	615.39	728.48	828.54	928.60	1029.65	
b_n found	[M+H-H ₂ O] ⁺	-	-	324.11	424.19	524.21	-	-	850.37	950.55	1050.91	1151.64
b_n found	[M+H] ⁺	140.95	241.03	342.12	442.21	-	-	-	-	1068.88	1169.70	
b_n calc.	[M+H] ⁺	141.13	241.19	342.24	442.30	542.37	642.43	755.51	868.60	968.66	1068.72	1169.77
		FA	Dab (1)	Thr (2)	Dab (3)	Dab (4)	Dab (5)	Leu (6)	Leu (7)	Dab (8)	Dab (9)	Thr (10)
y_n calc.	[M+H] ⁺	1169.77	1029.65	929.59	828.54	728.48	628.41	528.35	415.27	302.18	202.12	102.06
y_n found	[M+H] ⁺	1169.70	1029.20	929.17	828.23	728.24	628.23	528.20	415.24	302.15	202.04	-
y_n found	[M+H-H ₂ O] ⁺	1151.64	-	911.21	810.10	710.21	610.22	510.22	397.25	284.15	184.04	-

B

b_n found	[M+H-H ₂ O] ⁺	-	209.00	309.10	409.15	510.12	610.09	710.10	811.00	911.04		
b_n found	[M+H] ⁺	-	227.03	327.12	427.18	528.13	628.12	728.12	-	929.26		
b_n calc.	[M+H] ⁺	114.09	227.18	327.24	427.30	528.35	628.41	728.48	829.53	929.59		
b_n found	[M+H-H ₂ O] ⁺	-	196.00	309.10	409.15	509.12	610.09	710.10	-	911.04	1011.35	
b_n found	[M+H] ⁺	101.00	214.02	327.12	427.18	-	628.12	728.12	-	929.26	1029.72	
b_n calc.	[M+H] ⁺	101.07	214.16	327.24	427.30	527.37	628.41	728.48	828.54	929.59	1029.65	
			Dab (5)	Leu (6)	Leu (7)	Dab (8)	Dab (9)	Thr (10)	Dab (4)	Dab (3)	Thr (2)	Dab (1)
y_n calc.	[M+H] ⁺	1029.65	929.59	816.50	703.42	603.36	503.29	402.25	302.18	202.12	101.07	
y_n found	[M+H] ⁺	1029.72	929.26	816.08	-	603.05	503.10	402.13	302.08	201.97	101.00	
y_n found	[M+H-H ₂ O] ⁺	1011.35	911.04	-	-	-	485.12	-	284.05	183.96	-	

Figure 7. Sequence of the sodium adduct of polymyxin E2 (precursor ion [M + Na]⁺ = 1191.8 derived from LIFT-MALDI-TOF/TOF product ion spectra which were taken either starting from the fatty acid constituent or the first amino acid Dab (1) (A) as well as from Dab (5) and Leu (6) (B) modelling the polymyxin structure from series of b_n and y_n – ions.

b_n found	[M+H-H ₂ O] ⁺	-	184.01	284.13	385.23	485.25	598.26	711.30	811.27	-	1012.38	-	
b_n found	[M+H] ⁺	101.00	202.02	302.14	403.23	503.24	-	-	-	-	1030.64	1176.52	
b_n calc.	[M+H] ⁺	101.07	202.12	302.18	403.23	503.29	616.38	729.46	829.53	929.59	1030.64		
b_n found	[M+H-H ₂ O] ⁺	-	223.07	324.18	424.27	-	-	738.28	-	951.29	-	1152.55	
b_n found	[M+H] ⁺	141.00	241.09	342.20	442.20	-	-	-	-	-	1170.24	1316.16	
b_n calc.	[M+H] ⁺	141.13	241.19	342.24	442.30	543.35	643.41	756.50	869.58	969.64	1069.71	1170.75	1316.00
		FA	Dab (1)	Thr (2)	Dab (3)	Thr (4)	Dab (5)	Leu (6)	Leu (7)	Dab (8)	Dab (9)	Thr (10)	?
y_n calc.	[M+H] ⁺	1030.64	930.57	829.53	729.46	628.41	528.35	415.27	302.18	202.12	102.06		
y_n found	[M+H] ⁺	1030.64	-	-	-	-	528.35	415.25	302.14	202.02	102.00		
y_n found	[M+H-H ₂ O] ⁺	1012.38	-	811.27	711.30	-	510.32	397.23	284.13	184.01	-		

Figure 8. Sequence determination of the modified derivative of polymyxin E1 (precursor ion [M + H]⁺ = 1316.16) by LIFT-MALDI-TOF/TOF mass spectrometry.

Table 3. Modeling of the structure of the polymyxin E-derivative with a molecular mass of $m/z = 1316.2$ by combination of nearest neighbor relationships obtained by MALDI-TOF MS.

	<i>m/z</i>	
	calc.	found
a) Dipeptide fragments		
C9-FA-Dab	141.13	141.03
Dab-Thr	202.12	202.02
Thr-Dab	202.12	202.02
Dab- <u>Thr</u>	202.12	202.02
<u>Thr</u> -Dab	202.12	202.02
Dab-Leu	214.16	214.06
Leu-Leu	227.18	227.08
Leu-Dab	214.16	214.06
Dab-Dab	201.13	201.03
Dab-Thr	202.12	202.02
Thr + 145.41	247.47	-
b.) Tripeptide fragments		
C9-FA-Dab-Thr	342.24	324.18*
Dab-Thr-Dab	302.18	302.14
Thr-Dab- <u>Thr</u>	303.17	285.11*
Dab- <u>Thr</u> -Dab	302.18	302.14
<u>Thr</u> -Dab-Leu	315.20	297.17*
Dab-Leu-Leu	327.24	327.21
Leu-Leu-Dab	327.24	327.21
Leu-Dab-Dab	314.22	314.18
Dab-Dab-Thr	302.17	302.14
Dab-Thr + 145.41	347.43	-

Table 3. Cont.

c.) Tetrapeptide fragments		
C9-FA-Dab-Thr-Dab	442.30	442.20
Dab-Thr-Dab- <u>Thr</u>	403.23	403.23
Thr-Dab- <u>Thr</u> -Dab	403.23	403.23
Dab- <u>Thr</u> -Dab-Leu	415.27	415.25
<u>Thr</u> -Dab-Leu-Leu	428.29	410.28*
Dab-Leu-Leu-Dab	427.30	427.26
Leu-Leu-Dab-Dab	427.30	427.26
Leu-Dab-Dab-Thr	415.27	415.25
Dab-Dab-Thr + 145.41	442.59	447.31
d.) Pentapeptide fragments		
C9-FA-Dab-Thr-Dab- <u>Thr</u>	543.35	507.28**
Dab-Thr-Dab- <u>Thr</u> -Dab	503.35	503.25
Thr-Dab- <u>Thr</u> -Dab-Leu	516.31	498.25*
Dab- <u>Thr</u> -Dab-Leu-Leu	528.35	528.35
<u>Thr</u> -Dab-Leu-Leu-Dab	528.35	528.35
Dab-Leu-Leu-Dab-Dab	527.37	-
Leu-Leu-Dab-Dab-Thr	528.35	528.35
Leu-Dab-Dab-Thr + 145.41	560.68	-

Thr in position 4 is underlined. * means $[M + H - H_2O]^+$. ** means $[M + H - 2H_2O]^+$.

Plant growth promoting rhizobacteria and endophytes, like *Bacilli* and *Paenibacilli*, produce a wide spectrum of volatile organic compounds (VOCs), which exhibit a high chemical diversity and manifold activities. In this work we investigated the volatilomes of *Paenibacillus polymyxa* DSM 32871 and M1, which were grown in four different cultivation media (NA, LB, TSA and Landy). The obtained results summarized in Table 4 show that the production of VOCs by such organisms is strain and medium dependent.

Table 4: Microbial volatile organic compounds produced by the *Paeoniabacillus polymyxa* strains DSM32871 and M1 on different media. Identification was performed via HS-SPME GC-MS, matching to the NIST Mass Spectral Database and confirmation by the Kovats-Index. * Assignment as mVOCs refers to the absence in the mVOC database (Lerfack et al. 2018).

Compound	Kovats index	M1						DSM32871						Biological function	Reference
		NA	LB	TSA	LANDY	NA	LB	TSA	LANDY	NA	LB	TSA	LANDY		
Methanethiol	400	x		x						x				Broccoli and lettuce seed germination inhibition	Lo Cantore et al., 2015 [62]
Acetone	455		x	x	x					x				Potential contribution to inhibition of diverse fungi	Stolzky and Schenck, 1976 [63]
1,4-Pentadiene	518	x	x	x					x					n.a.	
n-Hexane	602												x	n.a.	
2-Methyl-1-propanol*	618	x												n.a.	
3-Propoxy-1-propene*	646		x											n.a.	
3-Methylpentane	650	x		x	x				x					A biomarker for a breath test for detection of caries	Hertel et al., 2016 [64]
2-Methylbutanal	656			x						x				n.a.	
2-Methylbutanenitrile*	699			x										n.a.	
Acetoin	709	x	x	x					x	x				Plant growth promotion and ISR activation in <i>A. thaliana</i> , increase of root length and number of lateral roots in <i>Lactuca sativa</i>	Ryu et al., 2003, 2004; Rudrappa et al., 2010; Fincheira et al., 2016 [43,47,58,61]
1-Chloropentane	725													n.a.	
2-Methyl-1-butanol	726	x	x		x				x	x				Inhibition of appressoria germination and germination of <i>Phyllosticta citricarpa</i>	Toffano et al., 2017 [57]
3-Methyl-1-butanol	727	x	x	x					x	x				Growth promotion and enhanced salinity tolerance of <i>Arabidopsis thaliana</i>	Ledger et al., 2016 [60]
Dimethyl sulfone	733	x												n.a.	
2,3-Butanediol	743														
Butyl acetate	802	x												Enhanced growth of tobacco plants and ISR against <i>Erwinia carotovora</i>	Han et al. 2006 [59]
3-Methylbutyl acetate	864	x												n.a.	
2-Heptanone	881	x												n.a.	
1-Octen-3-ol	969			x						x				Inhibit the development of <i>Arabidopsis thaliana</i> and modify its oxidative metabolism	Spilvallo et al., 2007 [65]
2-Ethyl-1-hexanol	1018	x		x						x				Inhibition of mycelial growth of <i>S. sclerotiorum</i> & reduction of sclerotial germination	Fernando et al., 2005 [55]
2-Isopropyl-3-methylpyrazine*	1033		x							x				n.a.	
2-Isopropyl-5-methylpyrazine	1034				x									n.a.	
3-Isopropyl-2,5-dimethylpyrazine	1129		x							x				n.a.	
2-Decanone	1152	x	x	x	x				x	x				Inhibition of mycelial growth of <i>Rhizoctonia solani</i>	Weise et al., 2012 [66]
2-Decanol	1166	x	x	x					x					n.a.	
2,3-Diethyl-5-methylpyrazine*	1261	x												n.a.	
2-Isobutyl-3-isopropylpyrazine*	1267	x	x	x					x	x				n.a.	

The identification of microbial volatile organic compounds (mVOCs) was performed via HS-SPME GC-MS, compared to the NIST MS 14 database and confirmed via Kovats indices. In total, 25 different volatile compounds could be identified in the headspace of *P. polymyxa* M1. In contrast to M1, only 20 volatile substances were detected as products of *P. polymyxa* DSM 32871. Interestingly, M1 exhibited the broadest array of mVOCs when grown on NA, whereas DSM 32871 produced the highest number of volatiles cultivated in TSA. Both strains produced a mixture of ketones, alcohols, alkanes, alkenes, and a variety of alkylpyrazines. The volatilomes of *P. polymyxa* DSM 32871 and M1 are highly overlapping with n-hexane being the sole compound, which could only be found in DSM 32871. Five compounds were unique to M1: 2-methyl-1-propanol, 2-methylbutanenitrile, dimethyl sulfone, butyl acetate, 3-methylbutyl acetate and 2-heptanone. In comparison to other plant growth promoting rhizobacteria of the order Bacillales, such as *Bacillus subtilis*, *Bacillus atrophaeus*, *Bacillus amyloliquefaciens*, *Bacillus velezensis*, and *Bacillus licheniformis* [50], both *P. polymyxa* strains emitted a variety of alkylpyrazines. In previous studies, alkylpyrazines exhibited antibacterial, antifungal, antimycobacterial, algicidal and antiviral activities [51-54]. Additionally, 2-methyl-1-butanol, 2-heptanone and 2-ethyl-1-hexanol revealed growth inhibition against *Agrobacterium tumefaciens* C58 and *Synechococcus* sp. PCC 7942 as well as fungal pathogens, such as *Phyllosticta citricarpa* and *Aspergillus fumigatus* [55-57]. Acetoin, 2,3-butanediol and 3-methyl-1-butanol can be found in the volatilomes of DSM 32871 and M1. These compounds are known for their plant growth promoting effect and induce systemic resistance (ISR) in distinct plants [43, 47, 58-61]. Examples for medium specificity included 2,3-butanediol which was formed by both strains only in the Landy medium, while 1-octen-3-ol and 2-ethyl-1-hexanol have been detected specifically in the TSA-medium.

The so far known biological functions of the observed volatiles are summarized in the right part of Table 4 [43,47,55,57-60, 62-66]. However, their biological effects and their underlying mode of action still need to be investigated.

3. Discussion

In this work we investigated the biosynthetic potential of the *P. polymyxa* strains DSM 32871 and M1. Both strains produce among some other bioactive compounds three lipopeptide complexes, the fusaricidins; the polymyxins and the tridecaptins. Our efforts were focused on the mass spectrometric analysis of the fusaricidins and polymyxins formed by the DSM 32871 strain, which were compared with those produced by the well characterized M1 strain [10,11, 39]. Both lipopeptide families are of high commercial interest because of their potential importance for applications both in agrobiotechnology and medicine.

The fusaricidins being the main products of DSM 32871 and M1 are known to exert potent antifungal activities. They show an unusual complexity because of manifold variations both in their peptide moiety as well as in their fatty acid part. For the reference strain M1 more than 80 variants have been reported so far [11]. Interestingly,

by MALDI-TOF mass spectrometric analysis of the fusaricidin complex of strain DSM 32871 three novel series of yet unknown fusaricidins were detected specifically when cultivated in the Landy/LOP medium. Prominent mass peaks of high intensity were found for fusaricidin variants modified at the free hydroxyl group of their allo-Thr component in position 4 by esterification with an alanine residue. Small amounts of such species have previously been found also for strain M1 specifically for fusaricidin C and D [10]. Another set of novel fusaricidins was detected, which are modified by an additional OH-group in their fatty acid part, which still remains to be precisely located. Fusaricidins have been utilized for biocontrol of numerous fungal plant diseases [26-30]. The aim of future studies will be the purification and provision in semi/preparative scale of selected fusaricidins by high resolution separation techniques for biocontrol applications in plant biotechnology.

Another prominent lipopeptide family produced by *P. polymyxa* DSM 32871 and M1 are the polymyxins which are cyclic decapeptides. They are well suited to inactivate Gram-negative pathogens, such as *Klebsiella*, *Enterobacteriaceae*, *A. baumannii* and *P. aeruginosa* [37-39]. DSM 32871 produces polymyxins E (colistins), while M1 forms polymyxins P. Polymyxins were discovered in 1947 (Stansly et al. 1947) and used for at least two decades as efficient antibiotics. Due to nephrotoxic and neurotoxic side effects they were taken from the market, however, recently polymyxins were retrieved again as last-resort antibiotics to counteract multiresistant super bugs [31,36-38]. High financial investment is made in several countries to optimize their structure, activities and pharmacokinetic properties with the aim to create novel efficient agents to contribute to the pertinent problem to overcome antibiotic multiresistance which is one of the most urgent issues to protect mankind against otherwise invincible dangerous pathogens.

By MALDI-TOF mass spectrometric analysis of the polymyxin E and P complexes produced by DSM 32871 and M1 we detected modified minor polymyxin species (see Table 2), which would be worth to be tested therapeutically. For example, for both polymyxin species we found variants which showed the polymyxin E or P sequence, but in addition contain a residue of 146 Da which could not yet be identified. We hypothesize that they may be glycosylated. The aim of our forthcoming studies will be to isolate and upgrade these variants in pure form by high resolution separation methodology for enabling structure elucidation and clinical testing.

Another important aspect of polymyxins is their application as biocontrol agents in agrobiotechnology to inactivate deleterious phytopathogens in order to prevent and cure plant diseases caused by Gram-negative plant pathogenic bacteria. For example, polymyxins P produced by the M1 strain were recently applied successfully against *Erwinia* strains [39].

In the third part of our work we investigated the manifold volatile organic compounds (VOCs) produced by *P. polymyxa* strains DSM 32871 and M1. VOCs attain increasing interest concerning their influence on the plant microbiomes and the communication between their members in the rhizosphere as well as their action inside plant tissues. Studies have been initiated to use VOCs produced by *P. polymyxa* strains as biocontrol

agents to inactivate phytopathogenic microorganisms and to induce systemic resistance against such pathogens [67-69]. The wide spectrum of volatiles produced by DSM 32871 and M1 is presented in Table 3. They comprise ketones, alcohols, alkanes and alkenes. A characteristic feature of different *Paenibacillus* species is their production of volatile pyrazine derivatives [51-54]. The specific equipment of the investigated *P. polymyxa* strains with VOCs revealed strain and medium dependent. Here the prospect of forthcoming studies is the investigation of their mechanism of action within the plant microbiome.

As a resumé of our detailed analyses of *P. polymyxa* strains we emphasize prospecting their potential for applications both for medical uses as well as in plant biotechnology.

4. MATERIALS AND METHODS

4.1 Materials

The matrices α -cyanohydroxycinnamic acid (CCA) and dihydroxy-benzoic acid (DHB) used for MALDI-TOF MS were obtained from Bruker (Bremen, Germany). Acetonitrile (ACN, HPLC grade) was purchased from Merck (Darmstadt, Germany), trifluoroacetic acid (TFA) from Sigma-Aldrich (Deisenhofen, Germany).

4.2 Cultivation of organisms

For the preparation of surface extracts of *Paenibacillus polymyxa* strains DSM 32871 and M1 were grown on agar plates using three cultivation media: a.) Lysogeny broth (Luria-Bertani) (LB) medium; b.) Landy medium [71] and c.) TSA-medium [50] solidified with 1.5% agar in Petri dishes for 24; 48 and 72 h at 30 °C. In addition, liquid fermentations were carried out in 100 ml Erlenmeyer flasks at 30 °C and 200 rpm in an orbital shaker (Buehler, Germany) in the LOP and LB medium to detect products released by the strains into the culture medium. The LOP-medium is a modified Landy medium which compared with the original version [71] contains higher amounts of glucose x H₂O (42 g/L) and Na-glutamate x H₂O (14 g/L).

4.3 Sample preparation

In order to obtain complete profiles of bioactive peptides produced by the investigated *P. polymyxa* strains DSM 32871 and M1, their products were detected by MALDI-TOF MS a.) in surface extracts of cells picked either from agar plates or harvested from liquid cultures by centrifugation for 10-20 min at 15000 rpm, b.) in culture supernatants after growth for 12; 24; 48; 72 and 96 h and c.) after disintegration cells by solubilization with 80% trifluoroacetic acid. For a.) a wire loop of cell material was picked, suspended in 50 μ L 50% acetonitrile/0.1% TFA and extracted for 15 min by vigorous vortexing. Finally, cells were spun down at 15000 rpm for 10 min.

4.4 HPLC fractionation of the bioactive compounds

330 μ L of the culture filtrate of *P. polymyxa* DSM 32871 cultivated in the LOP medium were diluted with 660 μ L 0.1% TFA. This sample was applied to a 300 SB-C8 Zorbax

column (4.6 x 250 mm; 5 μ m) and fractionated by reversed-phase HPLC using an Agilent (1200 series) instrument (Agilent Technologies, Waldbronn, Germany). Bioactive compounds were eluted by a two-step gradient from 0 to 70% eluent B in 70 min and from 70 to 95% eluent B in 5 min (70-75 min) followed by isocratic elution at 95% eluent B for 10 min at a flow rate of 0.5 mL/min. Eluent A was 0.1% TFA in water; eluent B was 99.9% ACN/0.1% TFA. Fractions of 1 mL were collected and evaporated to dryness in a SpeedVac evaporator (Uniequip, Martinsried, Germany). The dried material was dissolved in 30 μ L 50% aqueous ACN/0.1 TFA and tested mass spectrometrically.

4.5 Profiling of bioactive peptides by MALDI-TOF MS

Bioactive peptides of *P. polymyxa* DSM 32871 and M1 were detected and identified by MALDI-TOF MS, as outlined previously [11, 13; 50]. A Bruker Autoflex Speed TOF/TOF mass spectrometer (Bruker Daltonik, Bremen, Germany) was used with Smartbeam laser technology using a 1 kHz frequency-tripled Nd-YAG laser ($\lambda_{\text{ex}} = 355\text{nm}$). Samples (2 μ L) of surface extracts and culture supernatants were mixed with 2 μ L matrix solution (a saturated solution of α -hydroxy-cinnamic acid in 50% aqueous ACN containing 0.1% TFA), spotted on the target, air dried and measured. Mass spectra were obtained by positive-ion detection in reflector mode. Monoisotopic masses were obtained. Parent ions were detected with a resolution of 10.000. Sequence analysis of the lipopeptide products was performed by MALDI-LIFT-TOF/TOF mass spectrometry in laser induced decay (LID) mode [49]. The product ions in the LIFT-TOF/TOF fragment spectra were obtained with a resolution of 1000.

The mass spectrometry results did not allow optical isomers to be distinguished. Therefore, the configurations of the amino acid components were not indicated.

4.6 Identification of microbial volatiles using GC-MS

Paenibacillus polymyxa strains DSM 32871 and M1 were grown in 20 ml headspace vials (75.5 x 22.5 mm; Chromtech, Idstein, Germany) filled with 8 ml of a.) nutrient agar (Sifin Diagnostic GmbH, Berlin, Germany); b.) Lysogeny broth (Luria-Bertani) (LB) medium; c.) Landy medium [71] and d.) TSA-medium. Equal distribution was assured by parallel application of cell material in three vials per organism. After 24 h of incubation at 30 $^{\circ}\text{C}$, the volatiles accumulating inside the vials were measured by headspace solid-phase microextraction gas chromatography-mass spectrometry (HS-SPME GC-MS). Compound separation and detection was performed on a system combining a gas chromatograph 7890A with a quadrupol mass spectrometer 5975C (Agilent Technologies, Waldbronn, Germany). A SPME fibre consisting of divinylbenzene/carboxen/ polydimethylsiloxane (DVB/CAR/PDMS) was used for sampling (Sigma-Aldrich, St. Louis, USA). HS samples were separated in a (5%-phenyl)methylpolysiloxane column (60 m x 0.25 mm i.d.; 0.25 μ m film thickness; DB-5MS; Agilent Technologies, Waldbronn, Germany). Subsequently, electron ionization with 70 eV and detection in the mass range 25-350 Da were performed. The fiber was desorbed at 200 $^{\circ}\text{C}$ for 8 min to eliminate potential residues before initial

measurements. The inlet temperature was set to 270 °C. The temperature gradient of the column was maintained at 70 °C for 1.5 min, raised to 200 °C at a rate of 16 °C/min and finally kept at 200 °C for 0.5 min. The helium flow rate was adjusted to 1.2 ml/min. For identification of the volatiles the received spectra were matched to the NIST Mass Spectral Database.

Supplementary Materials: Figure S1: MALDI-TOF mass spectra of the fusaricidins in surface extracts and culture filtrates of *P. polymyxa* DSM 32871 and M1, Figure S2: MALDI-TOF mass spectra of the products found in fractions 22 until 31 of the HPLC-fractionation of the culture filtrate of DSM 32871, Figure S3: Upper part of the LIFT-MALDI-TOF/TOF product ion spectra of fusaricidin A ($[M + H]^+ = 883.74$) (A) and its derivatives with molecular masses $[M + H + 71]^+ = 954.63$ and $[M + H + 16]^+ = 899.43$, respectively, in the range from 280 Da up to the parent ion.

Author Contributions: KD, ES, PM and JV designed and developed the experimental strategy and the concept of the manuscript. ES, PM, KD and SH did the microbiological work (strain management and sample preparation). JV, SH and JJ performed the generation, evaluation and presentation of the mass spectrometric data. PM studied the volatilomes of the tested *P. polymyxa* strains. SH did the HPLC analysis. JV and PM wrote the manuscript. PL, TC and GB were involved in preparation and discussion of the manuscript. All authors contributed to the article and approved the submitted version.

Funding: This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 676480.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this article are available on request from the corresponding author.

Conflict of Interest: The authors declare no conflict of interest.

References

1. Cochrane, S.A.; Vederas, J.C. Lipopeptides from *Bacillus* and *Paenibacillus spp*: A gold mine of antibiotic candidates. *Med. Res. Rev.* **2016**, *36*, 4-31. doi: 10.1002/med.21321
2. Aleti, G.; Sessitsch, A.; Brader, G. Genome mining: Prediction of lipopeptides and polyketides from *Bacillus* and related *Firmicutes*. *Comput. Struct. Biotechnol.* **2015**, *13*, 192-203. dx.doi.org/10.1016/j.csbj.2015.03.003
3. Xie, J.; Shi, H.; Du, Z.; Wang, T.; Liu, X.; Chen, S. Comparative genomic and functional analysis reveal conservation of plant growth promoting traits in *Paenibacillus polymyxa* and its closely related species. *Sci. Rep.* **2016**, *6*, article 21329. doi: 10.1038/srep21329
4. Zhao, X.; Kuipers, O.P. Identification and classification of known and putative antimicrobial compounds produced by a wide variety of Bacillales species. *BMC Genomics* **2016**, *17*, article 882. doi: 10.1186/s12864-016-3224-y

5. Kajimura, Y.; Kameda, M. Fusaricidin A, a new depsipeptide antibiotic produced by *Bacillus polymyxa* KT-8. Taxonomy, fermentation, isolation, structure elucidation and biological activity. *J. Antibiot. (Tokyo)* **1996**, *49*, 129-135. doi: 10.7164/antibiotics.49.129
6. Kajimura, Y.; Kameda, M. Fusaricidin B, C and D, new depsipeptide antibiotics produced by *Bacillus polymyxa* KT-8. Isolation, structure elucidation and biological activity. *J. Antibiot. (Tokyo)* **1997**, *50*, 220-228. doi.org/10.7164/antibiotics.50.220
7. Kurusu, K.; Ohba, K.; Arai, T.; Fukushima, K. New peptide antibiotics LI-F03, F04, F05, F07 and F08 produced by *Bacillus polymyxa*. Isolation and characterization. *J. Antibiot. (Tokyo)* **1997**, *40*, 1506-1514. doi.org/10.7164/antibiotics.40.1506
8. Kuroda, J.; Fukai, J.; Konishi, M.; Ono, J.; Kurusu, K.; Nomura, T. Li-F antibiotics, family of antifungal cyclic depsipeptides produced by *Bacillus polymyxa* L-1129, *Heterocycles* **2000**, *53*, 1533-1549. doi: 10.3987/COM-00-8922
9. Kuroda, J.; Fukai, J.; Nomura, T. Collision-induced dissociation of ring-opened cyclic depsipeptides with a guanidino group by electrospray ionization trap mass spectrometry. *J. Mass Spectrom.* **2001**, *36*, 30-37. doi: 10.1002/jms.101
10. Vater, J.; Niu, B.; Dietel, K.; Borriss, R. Characterization of novel fusaricidins produced by *Paenibacillus polymyxa*-M1 using MALDI-TOF mass spectrometry. *J. Am. Soc. Mass Spectrom.* **2015**, *26*, 1548-1557. doi: 10.1007/s13361-015-1130-1
11. Vater, J.; Herfort, S.; Doellinger, J.; Weydmann, M.; Dietel, K.; Faetke, S.; Lasch, P. Fusaricidins from *Paenibacillus polymyxa* M-1, a family of lipohexapeptides of unusual complexity – a mass spectrometric study. *J. Mass Spectrom.* **2017**, *52*, 7-15. doi: 10.1002/jms.3891
12. Qiu, S.; Avula, B.; Guan, S.; Ravu, R.R.; Wang, M.; Zhao, J.; Khan, I.A.; Hinchee, M.; Li, X.-C. Identification of fusaricidins from the antifungal microbial strain *Paenibacillus* sp. MS2379 using ultra-high performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry. *J. Chromatogr. A* **2019**, *1586*, 91-100. doi: 10.1016/j.chroma.2018.12.007
13. Vater, J.; Herfort, S.; Doellinger, J.; Weydmann, M.; Borriss, R.; Lasch, J. Genome mining of the lipopeptide biosynthesis of *Paenibacillus polymyxa* E681 in combination with mass spectrometry: Discovery of the lipopeptide paeniloheptin. *ChemBioChem.* **2018**, *19*, 744-753. doi: 10.1002/cbic.201700615
14. Velkov, T.; Roberts, K.D.; Li, J. Rediscovering the octapeptins. *Nat. Prod. Rep.* **2017**, *34*, 295-309. doi: 10.1039/c6np00113k
15. Sogn, J.A. Structure of the peptide antibiotic polypeptin. *J. Med. Chem.* **1976**, *19*, 1228-1231. doi: 10.1021/jm00232a012
16. Qian, C.-D.; Liu, T.-Z.; Zhou, S.-L.; Ding, R.; Zhao, W.-P.; Li, O.; Wu, X.-C. Identification and functional analysis of gene cluster involvement in biosynthesis of the cyclic lipopeptide antibiotic pelgipeptin produced by *Paenibacillus elgii*. *BMC Microbiol.* **2012**, *12*, article 197. doi: 10.1186/1471-2180-12-197
17. Velkov, T.; Thompson, P.E.; Nation, R.L.; Li, J. Structure-activity relationships of polymyxin antibiotics. *J. Med. Chem.* **2010**, *53*, 1898-1916. doi: 10.1021/jm900999h
18. Kato, T.; Hino, H.; Shoji, J. The structure of tridecaptin A (studies on antibiotics from the genus *Bacillus*. XXIV). *J. Antibiot. (Tokyo)* **1978**, *31*, 652-661. doi: 10.7164/antibiotics.31.652
19. Kato, T.; Sakazaki, R.; Hino, H.; Shoji, J. The structures of tridecaptins B and C (studies on antibiotics from the genus *Bacillus*. XXV). *J. Antibiot. (Tokyo)* **1979**, *32*, 305-312. doi: 10.7164/antibiotics.32.305

20. Cochrane, S.A.; Lohans, C.T.; van Belkum, M.J.; Bels M.A.; Vederas, J.C. Studies on tridecapeptin B(1), a lipopeptide with activity against multidrug resistant Gram-negative bacteria. *Org. Biomol. Chem.* **2015**, *13*, 6073-6081. doi: 10.1039/c5ob0078c
21. Guo, Y.; Huang, E.; Yuan, C.; Zhang, L.; Yousef, A.E. Isolation of a *Paenibacillus* sp. strain and structural elucidation of its broad-spectrum lipopeptide antibiotic. *Appl. Environ. Microbiol.* **2012**, *78*, 3156-3165. doi: 10.1128/AEM.07782-11
22. Huang, E.; Guo, Y.; Yousef, A.E. Biosynthesis of the new broad-spectrum lipopeptide antibiotic paenibacterin in *Paenibacillus thiaminolyticus* OSY-SE. *Res. Microbiol.* **2014**, *165*, 243-251. doi: 10.1016/j.resmic.2014.02.002
23. Lal, S.; Tabacchioni, S. Ecology and biotechnological potential of *Paenibacillus polymyxa*: A minireview. *Indian J. Microbiol.* **2009**, *49*, 2-10. doi: 10.1007/s12088-009-0008-y
24. Eastman, A.W. Heinrichs, D.E.; Yuan, Z.C. Comparative and genetic analysis of four sequenced *Paenibacillus polymyxa* genomes reveals a diverse metabolism and conservation of genes relevant to plant-growth promotion and competitiveness. *BMC Genomics* **2014**, *15*, article 851. doi: 10.1186/1471-2164-15-851
25. Ali, M.A.; Lou, Y.; Hafeez, R.; Li, X.; Hossein, A.; Xie, T.; Lin, L.; Li, B.; Yin, Y.; Yan, J.; An, Q. Functional analysis of genome mining reveal high potential of biocontrol and plant growth promotion in nodule-inhabiting bacteria within *Paenibacillus polymyxa* complex. *Front. Microbiol.* **2021**, *11*, article 618601. doi: 10.3389/fmicb.2020.618601
26. Mousa, W.K.; Shearer, C.R.; Limay-Rios, V.; Zhou, T.; Raizada, M.N. Bacterial endophytes from wild maize suppress *Fusarium graminearum* in modern maize and inhibit mycotoxin accumulation. *Front. Plant Sci.* **2015**, *6*, article 805. doi:10.3389/fpls.2015.00805
27. Khan, M.S.; Gao, J.; Chen, X.; Zhang, M.; Yang, F.; Du, Y.; Moe, T.S.; Munir, I.; Xue, J.; Zhang, X. Isolation and characterization of plant growth-promoting endophytic bacteria *Paenibacillus polymyxa* SK1 from *Lilium lancifolium*. *BioMed Res. Internat.* **2020**, article ID 8650957. doi: 10.1155/2020/8650957
28. Li, Y.; Chen, S. Fusaricidin produced by *Paenibacillus polymyxa* WLY78 induces systemic resistance against *Fusarium* wilt of cucumber. *Int. J. Mol. Sci.* **2019**, *20*, article 5240. doi: 10.3390/ijms20205240
29. Beatty, P.H.; Jensen, S.E. *Paenibacillus polymyxa* produces fusaricidin-type antifungal antibiotics active against *Leptosphaeria maculans*, the causative agent of blackleg disease of canola. *Can. J. Microbiol.* **2002**, *48*, 159-169. doi: 10.1139/w02-002
30. Abdallah, Y.; Yang, M.; Zhang, M., Masum, M.M I.; Ogunyemi, S.O.; Hossein, A.; An, Q.; Yan, C.; Li, B. Plant growth promotion and suppression of bacterial leaf blight in rice by *Paenibacillus polymyxa* Sx3. *Let. Appl. Microbiol.* **2019**, *68*, 423-429. doi: 10.1111/lam.13117
31. Velkov, T.; Roberts, K.D.; Nation, R.L.; Wang, J.; Thompson, P.E.; Li, J. Teaching old polymyxins new tricks: New-generation lipopeptides targeting Gram-negative superbugs. *ACS Chem. Biol.* **2014**, *9*, 1172-1177. dx.doi.org/10.1021/cb500080r
32. Suzuki, T.; Inouye, H.; Fujikawa, K.; Suketa, Y. Studies on the chemical structure of colistin. *J. Biochem.* **1963**, *54*, 25-33. doi: 10.1093/oxford journals.jbchem.a127742
33. Suzuki, T.; Hayashi, K.; Fujikama, K.; Tsukamoto, K. The chemical structure of polymyxin E: The identities of polymyxin E1 with colistin A and of polymyxin E2 with colistin B. *J. Biochem.* **1965**, *57*, 226-227. doi: 10.1093/oxford journals.jbchem.a128082
34. Govaerts, C.; Rozenski, J.; Orwa, J.; Roets, E.; Van Schepdael, A.; Hoogmartens, J. Mass spectrometric fragmentation of cyclic peptides belonging to the polymyxin and colistin antibiotics studied by ion trap and quadrupole/orthogonal-acceleration time-of-flight technology. *Rapid Commun. Mass Spectrom.* **2002**, *16*, 823-833. doi: 10.1002/rcm.644

35. Kimura, Y.; Murai, E.; Fujisawa, M.; Tatsuki, T.; Nobue, F. Polymyxin P, new antibiotic of polymyxin group. *J. Antibiot. (Tokyo)* **1969**, *22*, 449-450. doi:10.7164/antibiotics.22.449
36. Brown, P.; Dawson, M.J. Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections. *J. Antibiot. (Tokyo)* **2017**, *70*, 386-394. doi: 10.1038/ja.2016.146
37. Vaara, M. Polymyxins and their potential next generation as therapeutic antibiotics. *Front. Microbiol.* **2019**, *10*, article 1689. doi: 10.3389/fmicb.2019-01689
38. Nang, S.C.; Azad, M.A.K.; Velkov, T.; Zhou, Q.; Li, J. Rescuing the last-line polymyxins: Achievements and challenges. *Pharmacol. Rev.* **2021**, *73*, 679-728. doi.org/10.1124/pharmrev.120.000020
39. Niu, B.; Vater, J.; Rueckert, C.; Blom, J.; Lehmann, M.; Ru, J.-J.; Chen, X.-H.; Wang, Q.; Borriss, R. Polymyxin P is the active principle in suppressing phytopathogenic *Erwinia spp.* by the biocontrol rhizobacterium *Paenibacillus polymyxa* M-1. *BMC Microbiol.* **2013**, *13*, article 137. doi: 10.1186/1471-2180-13-137
40. Audrain, B.; Farag, M.A.; Ryu, C.M.; Ghigo, J.M. Role of bacterial volatile compounds in bacterial biology. *FEMS Microbiol. Rev.* **2015**, *39*, 222-233. doi: 10.1093/femsre/fuu013
41. Kanschiswamy, C.N. Malnoy, M.; Maffei, M.E. Chemical diversity of microbial volatiles and their potential for plant growth and productivity. *Front. Plant Sci.* **2015**, *6*, article 151. doi: 10.3389/fpls.2015.00151
42. Kai, M. Diversity and distribution of volatile secondary metabolites throughout *Bacillus subtilis* isolates. *Front. Microbiol.* **2020**, *11*, article 559. doi: 10.3389/fmicb.2020.00559
43. Ryu, C.-M.; Farag, M.A.; Hu, C.-H.; Reddy, M.S.; Wei, H.-X.; Pare, P.W.; Kloepper, J.W. Bacterial volatiles promote growth in *Arabidopsis*. *Proc. Natl. Acad. Sci.* **2003**, *100*, 1017-1026. doi: 10.1073/pnas.0730845100
44. Asari, S.; Matzen, S.; Petersen, M.A. Bejai, S.; Meijer, J. Multiple effects of *Bacillus amyloliquefaciens* volatile compounds: plant growth promotion and growth inhibition of phytopathogens. *FEMS Microbiol. Ecol.* **2016**, *92*, fiw 070. doi: 10.1093/femsec/fiw070
45. Wu, Y.; Zhou, J.; Li, C.; Ma, Y. Antifungal and plant growth promotion activity of volatile organic compounds produced by *Bacillus amyloliquefaciens*. *Microbiol. Open* **2018**, *8*. doi: 10.1602/mb03.813
46. Kloepper, J.W.; Ryu, C.-M.; Zhang, S. Induced systemic resistance and promotion of plant growth by *Bacillus spp.* *Phytopathol.* **2004**, *94*, 1259-1266. doi: 10.1094/phyto.2004.94.11.1259
47. Ryu, C.-M.; Farag, M.A.; Hu, C.-H.; Reddy, M.S.; Klöpffer, J.W.; Pare, P.W. Bacterial volatiles induce systemic resistance in *Arabidopsis*. *Plant Physiol.* **2004**, *134*, 1017-1026. doi: 10.1104/pp.103.026583
48. Farag, M.A.; Ryu, C.-M.; Sumner, L.W.; Pare, P.W. GC-MS SPME profiling of rhizobacterial volatiles reveals prospective inducers of growth promotion and induced systemic resistance in plants. *Phytochem.* **2006**, *67*, 2262-2268. doi: 10.1016/j.phytochem.2006.07.021
49. Suckau, D.; Resemann, A.; Schuerenberg, M.; Hufnagel, P.; Franzen, J.; Holle, A. A novel MALDI LIFT-TOF/TOF mass spectrometer for proteomics. *Anal. Bioanal. Chem.* **2003**, *376*, 952-965. doi: 10.1007/s00126-003-2057-0
50. Mülner, P.; Schwarz, E.; Dietel, K.; Junge, H.; Herfort, S.; Weydmann, M.; Lasch, P.; Cernava, T.; Berg, G.; Vater, J. Profiling for bioactive peptides and volatiles of plant growth promoting strains of the *Bacillus subtilis* complex of industrial relevance. *Front. Microbiol.* **2020**, *11*, article 1432. doi: 10.3389/fmicb.2020.01432
51. Ferreira, S.B.; Kaiser, C.R. Pyrazine derivatives: A patent review (2008-present). *Expert Opinion on Therapeutic Patents.* **2012**, *22*, 1033-1151. doi: 10.1517/13543776.2012.714370
52. Haidar, R.; Roudet, J.; Bonnard, O.; Dufour, M.C.; Corio-Costet, M.F.; Fert, M.; Gautier, P.; Deschamps, A.; Fermaud, M. Screening and modes of action of antagonistic bacteria to control the fungal pathogen *Phaeoemoniella chlamydospora* involved in grapevine trunk diseases. *Microbiol. Res.* **2016**, *192*, 172-184. doi: 10.1016/j.micres.2016.07.003

53. Kusstatscher, P.; Cernava, T.; Liebming, S.; Berg, G. Replacing conventional decontamination of hatching eggs with a natural defense strategy based on antimicrobial volatile pyrazines. *Sci. Rep.* **2017**, *7*, 1-8. doi: 10.1038/s41598-017-13579-7
54. Mülner, P.; Wagner, P.; Bergna, A.; Sarajlic, D.; Gstötenmayr, B.; Dietel, K.; Grosch, R.; Cernava, T.; Berg, G. Microbiota associated with sclerotia of soilborne fungal pathogens – a novel source of biocontrol agents producing bioactive volatiles. *Phytobiomes J.* **2019**, *3*, 125-136. doi: 10.1094/PBIOMES-11-18-0091-R
55. Fernando, W.G.D.; Ramarathnam, R.; Krishnamoorthy, A.S.; Savchuk, S.C. Identification and use of potential bacterial organic antifungal volatiles in biocontrol. *Soil Biol. Biochem.* **2005**, *37*, 955-964. doi: 10.1016/j.SOILBIO.2004.10.021
56. Popova, A.A.; Koksharova, O.A.; Lipasova, V.A.; Zaitseva, J.V.; Katkova-Zhukotskaya, O.A.; Eremina, S.I.; Mironov, A.S.; Chernin, L.S.; Khmel, I.A. Inhibitory and toxic effects of volatiles emitted by strains of *Pseudomonas* and *Serratia* on growth and survival of selected microorganisms, *Caenorhabditis elegans* and *rosophila melanogaster*. *Biomed. Res. Internat.* **2014**, *2014*, 125704. doi: 10.1155/2014/125704
57. Toffano, L.; Fialho, M.B.; Pascholati, S.F. Potential of fumigation of orange fruits with volatile organic compounds produced by *Saccharomyces cerevisiae* to control citrus black spot disease at postharvest. *Biol. Control*, **2017**, *108*, 77-82. doi: 10.1016/j.biocontrol.2017.02.009
58. Fincheira, P.; Venthur, H.; Mutis, A.; Parada, M.; Quirot, A. Growth promotion of *Lactuca sativa* in response to volatile organic compounds emitted from diverse bacterial species. *Microbiol. Res* **2016**, *193*: 39–47. doi: 10.1016/j.micres.2016.09.008
59. Han, S.H.; Lee, S.J.; Moon, J.H.; Park, K.H.; Yang, K.Y.; Cho, B.H.; Kim, K.Y.; Kim, Y.W.; Lee, M.C.; Anderson, A.J.; Kim, Y.C. GacS-dependent production of 2R, 3R butanediol by *Pseudomonas chlororaphis* 06 is a major determinant for eliciting resistance against *Erwinia carotovora* but not against *Pseudomonas syringae* pv. *Tabaci*. *Mol. Plant Microbe Interactions*, **2006**, *19*, 924-930. doi: 10.1094/MPMI-19-0924
60. Ledger, T.; Rojas, S.; Timmermann, T.; Pinedo, I.; Poupin, M.J.; Garrido, T.; Richter, P.; Tamayo, J.; Donoso, R. Volatile-mediated effects predominate in *Paraburkholderia phytofirmans* growth promotion and salt stress tolerance of *Arabidopsis thaliana*. *Front.Microbiol.* **2016**, *7*, article 1838. doi: 10.3389/fmicb.2016.01838
61. Rudrappa, T.; Biedrzycki, M.L.; Kunjeti, S.G.; Donofrio, N.M.; Czymmek, K.J.; Paré, P.W.; Bais, H.P. The rhizobacterial elicitor acetoin induces systemic resistance in *Arabidopsis thaliana*. *Commun. Integr. Biol.* **2010**, *3*, 130-138. doi: 10.4161/cib.3.2.10584
62. Lo Cantore, P.; Giorgio, A.; Iacobellis, N.S. Bioactivity of volatile organic compounds produced by *Pseudomonas tolaasii*. *Front. Microbiol.* **2015**, *6*, article 1082. doi: 10.3389/fmicb.2015.01082
63. Stotzky, G.; Schenk, S. Volatile organic compounds and microorganisms. *CRC Crit. Rev. Microbiol.* **1976**, *4*, 333-382. doi: 10.3109/10408417609102303
64. Hertel, M.; Preissner, R.; Gilissen, B.; Schmidt-Westhausen, A.M.; Paris, S.; Preissner, S. Detection of signature volatiles for cariogenic microorganisms. *Eur. J. Clin. Microbiol. Infect Dis.* **2016**, *35*, 235-244. doi: 10.1007/s.10096-015-2536-1
65. Splivallo, R.; Novero, M.; Berteà, C.M.; Bossi, S.; Bonfante, P. Truffle volatiles inhibit growth and induce an oxidative burst in *Arabidopsis thaliana*. *New Phytol.* **2007**, *175*, 417-424. doi: 10.1111/j.1469-8137.2007.02141.x
66. Weise, T.; Kai, M.; Gummesson, A.; Troeger, A.; von Reuß, S.; Piepenborn, S.; Kosterka, F.; Sklorz, M.; Zimmermann, R.; Francke, W.; Piechulla, B. Volatile organic compounds produced by the phytopathogenic bacterium *Xanthomonas campestris* pv. *vesicatoria* 85-10. *Beilstein J. Org. Chem.* **2012**, *8*, 579-596. doi: 10.3762/bjoc.8.65

-
67. Stansly, P.G.; Schlosser, M.E. Studies on polymyxin: Isolation and identification of *Bacillus polymyxa* and differentiation of polymyxin from certain known antibiotics. *J. Bacteriol.* **1947**, *54*, 549-556. doi: 10.1128/jb.54.5.549-556.1947
 68. Rybakova, D.; Rack-Wetzlinger, U.; Cernava, T.; Schaefer, A.; Schmuck, M.; Berg, G. Aerial warfare: A volatile dialogue between the plant pathogen *Verticillium longisporum* and its antagonist *Paenibacillus polymyxa*. *Front. Plant Sci.* **2017**, *8*, article 1294. doi: 10.3389/fpls.2017.01294
 69. Cheng, W.; Yang, J.; Nie, Q.; Huang, D.; Yu, C.; Zheng, L.; Cai, M.; Thomashow, L.S.; Weller, D.M.; Yu, Z.; Zhang, J. Volatile organic compounds from *Paenibacillus polymyxa* KM2501-1 control *Meloidogyne incognita* by multiple strategies. *Sci. Rep.* **2017**, *7*, 16213. doi: 10.1038/s41598-017-16631.8
 70. Lee, B.; Farag, M.A.; Park, H.B.; Kloepper, J.W.; Lee, S.H.; Ryu, C.-M. Induced resistance by a long-chain bacterial volatile: Elicitation of plant systemic defense by a C13 volatile produced by *Paenibacillus polymyxa*. *Plos One.* **2012**, *7*, e48744. doi: 10.1371/journal.pone.0048744
 71. Landy, M.; Warren, G.H.; Rosenman, S.B.; Colio, L.G. Bacillomycin; an antibiotic from *Bacillus subtilis* active against pathogenic fungi. *Proc. Soc. Exp. Biol. Med.* **1948**, *67*, 539-541. doi: 10.3181/003379727-67-16367